Global Type 2 Diabetes Market - Expected Increase in the Diagnosed Prevalent Cases of T2D to 212,237,385 by 2028 - ResearchAndMarkets.com

DUBLIN--()--The "Type 2 Diabetes: Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Summary:

Type 2 diabetes (T2D), formerly known as non-insulin-dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency (World Health Organization, 2016a). T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (International Diabetes Federation, 2014).

The Publisher epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the diagnosed prevalent cases of T2D in the 9MM. The publisher epidemiologists applied the prevalence of T2D drawn from the above sources to each country's population to calculate the prevalent cases of T2D and major comorbidities of T2D, such as chronic kidney disease (CKD), cardiovascular disease (CVD), obesity, hypertension, dyslipidemia, and atherosclerosis in the diagnosed T2D prevalent population.

The following data describes the epidemiology of T2D. In the 9MM, the publisher epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 164,826,095 diagnosed prevalent cases in 2018 to 212,237,385 diagnosed prevalent cases in 2028, with an annual growth rate (AGR) of 2.88% during the forecast period. India will have the highest number of diagnosed prevalent cases of T2D among the 9MM throughout the forecast period, while Spain will have the lowest. When examining the AGR of diagnosed prevalence of T2D in individual markets, the publisher epidemiologists forecast that France will see the highest AGR of 5.60% during the forecast period, while Japan will show the lowest AGR of 0.39%.

Scope:

  • The Type 2 Diabetes Epidemiology Report provides an overview of the risk factors and global trends of Type 2 Diabetes (T2D) in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
  • This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age, and sex. Additionally, the report provides a forecast for the prevalent cases of major comorbidities of T2D, such as chronic kidney disease (CKD), cardiovascular disease (CVD), obesity, hypertension, dyslipidemia, and atherosclerosis in the diagnosed T2D prevalent pool.
  • The T2D epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy:

  • Develop business strategies by understanding the trends shaping and driving the global T2D market.
  • Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.
  • Understand magnitude of T2D population by major comorbidities

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Type 2 Diabetes: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of T2D

3.4.3 Forecast Assumptions and Methods: Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D

3.4.4 Forecast Assumptions and Methods: Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D

3.4.5 Forecast Assumptions and Methods: Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D

3.4.6 Forecast Assumptions and Methods: Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D

3.4.7 Forecast Assumptions and Methods: Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D

3.4.8 Forecast Assumptions and Methods: Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D

3.5 Epidemiological Forecast for Type 2 Diabetes (2018-2028)

3.5.1 Diagnosed Prevalent Cases of T2D

3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D

3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D

3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About The Publisher

4.4 Contact Us

4.5 Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/m1ss6k

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900